Cicada HealthTech Hub Masterclass: Going Global - choosing & navigating the right market for my innovations
Description
Early-stage founders and innovators: learn how to choose the right market before taking a health technology global, at this free Cicada HealthTech Hub masterclass on 5 November at the Western Sydney Startup Hub, with guidance from Austrade, global commercial leaders and founders who have done it.
For an early-stage health innovator, understanding the target market can be crucial in turning good technology into a viable venture, however simple or sophisticated that technology is.
This masterclass works through the questions founders and research teams face when they start thinking about where to launch. Do you go international first, or build at home? How do you read a political and investment landscape that keeps shifting, and still attract interest locally and from offshore? And how do payer value and reimbursement fit into a market decision from the very start, rather than as an afterthought?
Over a morning tea at the Western Sydney Startup Hub, join us to network with founders, export advisors and commercialisation experts and learn about the incentives and support available at a government level, the sector and learned experience.
Who this is for
This morning tea masterclass discussion is built for early to seed stage healthtech ventures who wants to hear and connect directly with sector representatives, industry partners who are weighing up where and when to take a health innovation to market.
What you'll take away
What to vs not to do when defining a market-first commercial strategy, before committing time and capital to a region
Industry insights on access and market entry compare across the US, APAC and Australia
Value proposition and market decision, and why they belong in the strategy early
A clear read on the current incentives, opportunities and government support for Australian health exporters
Honest accounts of the barriers and the mistakes to avoid, from people who have been through it
Agenda
10am Registration Open
10:30-11:15am Morning tea + Networking
11:15-11:20pm Welcome and Introductions
11:20-12:30pm Panel discussion
Topic: Going Global - considerations, strategies and navigating the right market for my innovations - Learned experience & market insights
Moderator: Angelica Lau
Panellists: Lance Chia, Hanh Hoang, Max Lau, Nicole Schonrock
12:50pm Conclude
-----------
Join us to connect directly with global commercial leaders, Austrade, InvestHK and founders who talk openly about the real barriers to going global, specifically in US and APAC markets. As the political landscape shifts the flow of investment, opportunity and access, this is a chance to learn what works, and what to avoid, from people who have done it.
Morning tea provided. Places are limited, so registration is encouraged early.
Presented by Cicada HealthTech Hub, in partnership with Brandon Capital and the NSW Government, supported by Western Sydney Startup Hub.
Don't miss this opportunity to gain valuable insights from industry experts and network with fellow health tech innovators.
Lineup
Angelica Lau, Program Manager Cicada Innovations (Moderator)
Angelica is passionate about supporting commercialisation and bridging innovations from bench to market, building trusted relationships and delivering programs that help Australian deep tech ventures grow. She leads the Health commercialisation programs at Cicada Healthtech Hub, dedicated to building relationships, connections and cultivating the Westmead health ecosystems, turning cutting edge science and research to policy and commercial success.
Lance Chia, Chairperson of Navi Medical Technologies and Lenexa Medical, and Managing Director of Ellenjay Asia Pacific
Lance has more than 40 years in health and medtech, beginning as a clinical biochemist before global leadership roles at ResMed, where as Head of Global Marketing he led device launches across APAC and EMEA. He now supports early-stage ventures through governance and board leadership, and is a Fellow of the AICD.
Hanh Hoang, Senior Export Adviser and TradeStart Adviser, Trade and International, Investment NSW
Hanh has more than 20 years in export development for Australian products and services, and since 2019 has advised hundreds of Sydney businesses under the Austrade and NSW Government remits, most prominently in life sciences and healthcare. She brings deep Asia market exposure and a strong record of converting opportunities into commercial results.
Nicole Schonrock, Head of Partnerships and Clinical Innovations, Hartwig Medical Foundation Australia
Nicole combines a multi-omic research background with more than nine years in business development across start-ups and global healthcare companies. She is working to scale precision oncology, with networks across the genomics ecosystem and expertise spanning cancer, rare disease, reproductive health and proactive screening.
Max Lau, Head of Investment Promotion, Invest HK
Max is the Head of Business & Talent Attraction/ Investment Promotion from Invest HK, engaging with Australian and New Zealand companies exploring the business opportunities in the Hong Kong and Asia market.
Jo Chaturvedi-Durant, Venture Partner, VU Venture Partners
Jo is a private markets and VC investor with 18 years’ experience in the investment management industry across traditional and alternative asset classes. She invests in frontier tech across stages, geographies and sectors focusing on technologies capable of reshaping industries at a global scale and backing exceptional founders.
FAQs
- What is the Cicada HealthTech Hub?
Cicada Innovations is proud to be collaborating with the Westmead Health & Innovation District, Australia’s fastest-growing health and innovation precinct, for this commercialisation masterclass series. These masterclasses are to help bridge the gap between research and commercialisation.
Find out more about the Cicada HealthTech Hub
The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.
Tickets for good, not greed Humanitix dedicates 100% of profits from booking fees to charity
